NCT05365035: A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
- State
- Under way
- Phase
- Phase 2
- People
- 60 planned
- Started
- 23 Sep 2022
- Primary completion
- 31 Dec 2027
- Arms
- cladribine, cytarabine, venetoclax, and azacitidine
- Results
- None posted
- 6 May 2022: Trial registered
- 23 Sep 2022: Trial started